It's Time to Join the Systems-Thinking Revolution
By: John Doyle, DrPH, MPH | August 13, 2013
The traditional biopharmaceutical business model is no longer viable, and if biopharma executives want to continue to be profitable in the future they need eradicate inefficiencies and silos, and figure out how to collaborate with other industry stakeholders toward common goals.
When they do this, they will finally be able to cut time and cost from their processes, and spread the risk more evenly among players, while bringing more transformative treatments to market.
But this transition won’t be easy. It means they have to think more holistically about their business processes, and actively pursue collaborative projects that have clearly defined cost, quality and value benefits for all partners.
Unfortunately, our recent survey suggests that while many healthcare industry stakeholders recognize the value of a systems-thinking model, few have made significant efforts to align with other stakeholder groups, or to develop the skills, processes and technology to effectively share knowledge and data.
Quintiles’ new Collaboration Mandate report explores the obstacles biopharma and other industry stakeholders face in moving to a systems-oriented approach, and how they can overcome them.
Our findings show:
You can learn more about our survey regarding the industry’s move to a systems-thinking environment by downloading The Collaboration Mandate.